ArticleTranslational gastroenterology and hepatology2026
Clinical and laboratory characteristics associated with ascites in patients with MASLD-related cirrhosis: a cross-sectional study.
Article in Translational gastroenterology and hepatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Metabolic dysfunction-associated steatotic liver disease (MASLD) is a prevalent condition globally. It is underexplored in Saudi Arabia, particularly its clinical and biochemical factors associated with hepatic decompensation (ascites) among MASLD-related cirrhosis. The objective is to describe and compare the demographic, clinical, biochemical, and laboratory profile of MASLD-related cirrhosis in the presence or absence of ascites. The importance of routine monitoring correlated with hepatic decompensation was also explored. Methods: This cross-sectional study was conducted, in which data were collected from hepatology electronic medical records at King Abdulaziz University Hospital for patients managed between January and July 2025. Eligible adults (≥18 years) had MASLD-related cirrhosis, defined by hepatic steatosis on imaging with at least one cardiometabolic risk factor and exclusion of other liver disease aetiologies, with cirrhosis confirmed by ultrasound, computed tomography (CT), transient elastography, or biopsy. Patients were classified by presence or absence of ascites, diagnosed clinically and/or by ultrasound. Demographic, anthropometric, haematological, and biochemical variables, together with the fibrosis-4 (FIB-4) index and non-alcoholic fatty liver disease (NAFLD) Fibrosis Score (NFS), were compared between groups using independent-samples t-tests (with Welch correction where indicated) and chi-square/Fisher's exact tests. Binary logistic regression was used to explore associations between clinical/laboratory variables and the presence of ascites, using SPSS version 27. Results: There were 41 MASLD cirrhosis patients (56.1% women, 68.3% Saudi): 14 (34.1%) with ascites and 27 (65.9%) without. Patients with ascites had significantly lower serum albumin (33.25±8.05 Conclusions: In this cross-sectional sample of Saudi patients with MASLD-related cirrhosis, lower serum albumin, lower ALT, and lower white cell count were associated with the presence of ascites; higher BMI showed a similar trend that did not reach significance. Given the cross-sectional design and small number of ascites cases, these findings should be interpreted as exploratory associations rather than predictors of decompensation, and do not by themselves support a claim that monitoring or modifying these markers would prevent progression to ascites. Larger, prospective, longitudinal studies are needed to determine whether these markers have predictive value for incident decompensation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.